Answers are grounded in this paper and cite their sources.
Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) with advanced liver fibrosis in metabolic bariatric surgery (MBS) candidates influences perioperative risk and management. The diagnostic performance of non-invasive liver tests (NITs) remains insufficiently validated in grade II-III obesity. We aimed to evaluate biopsy-validated diagnostic performance of liver NITs in this population. Methods Adults with grade II–III obesity and MASLD scheduled for MBS underwent preoperative vibration controlled elastography (VCTE) with controlled attenuated parameter (CAP) (Fibroscan®, Echosens, Fr), Fibrosis-4 index (FIB-4) and Fibroscan®-AST (FAST) score calculation and systematic intraoperative liver biopsy. Diagnostic performance was evaluated using receiver operating characteristic (AUROC) curve analysis and Youden index. Results Overall, 585 participants were included (BMI 44.7 ± 5.1 kg/m²; 40.8 ± 9.6 years, 87% female). Significant (≥F2) and advanced (≥F3) liver fibrosis prevalence was 6.3% and 3.9%. FIB-4 discrimination for ≥F3 was excellent (AUROC 0.91). An optimized cut-off of 1.07 yielded 96% sensitivity and 99.8% negative predictive value. VCTE showed an AUROC of 0.89 for ≥F3 with 97.8% success rate. For fibrosis ≥F3, using the cohort-derived FIB-4 threshold of 1.07 instead of 1.30 increased the sensitivity of sequential FIB-4/VCTE testing from 65.2% to 82.6%. CAP demonstrated good accuracy for steatosis detection (AUROC 0.80). FAST score was able to rule out at risk-MASH with negative predictive value over 97%. Conclusions In this large grade II-III obesity cohort, FIB-4 and VCTE demonstrated high accuracy for ruling out advanced fibrosis. A lower FIB-4 threshold of 1.07 improved the sensitivity of sequential FIB-4/VCTE testing; however, external validation is required before its clinical implementation. CAP and FAST provided good performance for steatosis and at-risk MASH detection. These results may support the incorporation of NITs into the routine preoperative evaluation of MBS candidates, allowing identification of patients requiring specialized hepatology care. Key points • Large biopsy-validated severe obesity cohort undergoing MBS. • FIB-4 showed excellent negative predictive value for advanced fibrosis. • FIB-4 cut-off 1.07 improved sensitivity for advanced fibrosis diagnosis. • VCTE showed strong accuracy for ≥F2 and ≥ F3 fibrosis detection.
No takes yet. Share an insight, caveat, or question.
Andrade et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: